ArticleCurrent microbiology2026
Enhanced Lichenysin Production in Bacillus licheniformis by Physicochemical Mutagenesis Combined with High-Throughput Screening.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Lichenysin is a cyclic lipopeptide secondary metabolite produced by Bacillus licheniformis, with excellent biocompatibility and diverse biological activities. It has broad application potential in biomedicine, agricultural pest control, energy production, and environmental remediation. Nevertheless, the improvement of wild strain with complex genetic backgrounds through genetic and metabolic pathway modifications poses significant challenges in terms of time and cost, which has become a bottleneck limiting the diversified development of lichenysin-producing strains. In this research, ultraviolet (UV) irradiation, N-methyl-N'-nitro-N-nitrosoguanidine (NTG), ethyl methanesulfonate (EMS) and composite mutagenesis strategies were systematically utilized to conduct multiple rounds of mutagenesis using Bacillus licheniformis Ali5 as the parental strain. Subsequently, the mutants were screened through high-throughput screening in a 96-well plate based on the hexadecylpyridinium chloride-fluorescein (CPC-FL) fluorescence detection principle. After two rounds of mutagenesis and genetic stability assessment, five high-yielding mutant strains with stable genetic traits (UV40-4, NT382-5, EMS191-1, NV341-3 and EV52-1) were successfully screened. The results of flask culture illustrated that the mutants were superior to the parental strain in biomass, the titer/OD
Indexed as
Identifiers
42905301What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.